MedTrace Logo

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

NCT02799095 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 243

Last updated 2025-05-21

Study results available
· View outcomes & findings →

Summary

To better understand the safety and tolerability of ALKS 4230 in humans

Conditions

Interventions

DRUG

ALKS 4230

Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period

DRUG

ALKS 4230 + pembrolizumab

IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle

Sponsors & Collaborators

  • Mural Oncology, Inc

    lead INDUSTRY

Principal Investigators

  • Medical Director · Mural Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-14
Primary Completion
2023-03-27
Completion
2023-08-02

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Poland
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02799095 on ClinicalTrials.gov